Business Description
LifeTech Scientific Corp
ISIN : KYG548721177
Compare
Compare
Traded in other countries / regions
01302.Hong Kong81X.GermanyLFTSF.USA IPO Date
2021-11-17Description
LifeTech Scientific Corp develops and manufactures also responsible for marketing of of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: Structural heart diseases business; Peripheral vascular diseases business and Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral vascular diseases business segment. Geographically, it derives a majority of revenue from China.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.97 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.86 | |||||
| Interest Coverage | 316.04 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.83 | |||||
| Beneish M-Score | -2.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.7 | |||||
| 3-Year EBITDA Growth Rate | -11.4 | |||||
| 3-Year EPS without NRI Growth Rate | 65.6 | |||||
| 3-Year FCF Growth Rate | -14.2 | |||||
| 3-Year Book Growth Rate | 11.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.17 | |||||
| 9-Day RSI | 48.79 | |||||
| 14-Day RSI | 51.41 | |||||
| 6-1 Month Momentum % | 3.1 | |||||
| 12-1 Month Momentum % | -41.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.68 | |||||
| Quick Ratio | 2.02 | |||||
| Cash Ratio | 1.26 | |||||
| Days Inventory | 609.88 | |||||
| Days Sales Outstanding | 36.58 | |||||
| Days Payable | 603 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.7 | |||||
| Shareholder Yield % | 1.95 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 78.58 | |||||
| Operating Margin % | 17.97 | |||||
| Net Margin % | 19.32 | |||||
| FCF Margin % | -4.51 | |||||
| ROE % | 7.38 | |||||
| ROA % | 5.44 | |||||
| ROIC % | 5.02 | |||||
| ROC (Joel Greenblatt) % | 8.78 | |||||
| ROCE % | 2.92 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.93 | |||||
| Forward PE Ratio | 13.58 | |||||
| PE Ratio without NRI | 31.74 | |||||
| Shiller PE Ratio | 34.55 | |||||
| Price-to-Owner-Earnings | 37.44 | |||||
| PEG Ratio | 3.97 | |||||
| PS Ratio | 4.65 | |||||
| PB Ratio | 1.74 | |||||
| Price-to-Tangible-Book | 2.33 | |||||
| Price-to-Operating-Cash-Flow | 19.73 | |||||
| EV-to-EBIT | 44.12 | |||||
| EV-to-EBITDA | 40.84 | |||||
| EV-to-Revenue | 3.82 | |||||
| EV-to-FCF | -87.59 | |||||
| Price-to-Projected-FCF | 1.48 | |||||
| Price-to-Median-PS-Value | 0.3 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.26 | |||||
| Price-to-Graham-Number | 1.81 | |||||
| Price-to-Net-Current-Asset-Value | 8.15 | |||||
| Earnings Yield (Greenblatt) % | 2.27 | |||||
| FCF Yield % | -0.96 | |||||
| Forward Rate of Return (Yacktman) % | 9.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LifeTech Scientific Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 164.208 | ||
| EPS (TTM) (€) | 0.007 | ||
| Beta | -0.03 | ||
| Volatility % | 54.97 | ||
| 14-Day RSI | 51.41 | ||
| 14-Day ATR (€) | 0.003535 | ||
| 20-Day SMA (€) | 0.1646 | ||
| 12-1 Month Momentum % | -41.15 | ||
| 52-Week Range (€) | 0.078 - 0.292 | ||
| Shares Outstanding (Mil) | 4,399.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LifeTech Scientific Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LifeTech Scientific Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
LifeTech Scientific Corp Frequently Asked Questions
What is LifeTech Scientific Corp(FRA:81X)'s stock price today?
The current price of FRA:81X is €0.16. The 52 week high of FRA:81X is €0.29 and 52 week low is €0.08.
When is next earnings date of LifeTech Scientific Corp(FRA:81X)?
The next earnings date of LifeTech Scientific Corp(FRA:81X) is .
Does LifeTech Scientific Corp(FRA:81X) pay dividends? If so, how much?
LifeTech Scientific Corp(FRA:81X) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers